Bevacizumab/carboplatin/paclitaxel.The article describes the case of a man who developed internal jugular vein thrombosis and pulmonary embolism after receiving chemotherapy with carboplatin, paclitaxel and bevacizumab.EBSCO_AspReactions Weekly
death life-threatening hospitalisation disability congenital anomaly requires intervention to prevent permanent impairment or damage A 55-year-old male, diagnosed with metastatic non-small cell lung cancer, received first-line chemotherapy with carboplatin AUC 5, paclitaxel 175 mg/m 2 and bevacizumab 15...
Case Report: A case of an advanced stage epithelial ovarian cancer (EOC) receiving a combination of bevacizumab, carboplatin and paclitaxel chemotherapy was reported. A 44-year-old woman was presented with abdominal discomfort and distention for 4 months. Bilateral 12 cm diameter ovarian tumors were...
Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy. Case Reports in Oncology 13: 373-378, No. 1, Jan-Apr 2020. Available from: URL: http://doi.org/10.1159/000506446 Download references Rights and permissions ...
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non–small cell lung cancer. JAMA. 2012;307(15):1593-1601. eTable 1. P Values for the Chi-Square Test Comparing Characteristics Between BCP and CP 2006-7 and Between BCP and CP 2002-5 Elderly Advanced ...
Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: ... ? 2022 Elsevier Inc.Objective: This multicenter, open-label, phase II study aimed to evaluate the efficacy and safety of paclitaxel–carboplatin, ...
INTRODUCTION: This phase II trial evaluated the efficacy and toxicity of the combination of paclitaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with carcinoma of unknown primary site (CUP). METHODS: Patients with previously untreated CUP (adenocarcinoma, poorly ...
The anti-VEGF antibody bevacizumab is indicated in combination with standard carboplatin-based regimens in platinum-sensitive disease3,4,5, and in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant patients6. Olaparib, an inhibitor of the enzyme poly-ADP-...
(4.4 vs. 2.8months;P<.001) and improved median postinduction overall survival (12.8 vs. 11.4months;P=.03) compared with the carboplatin/paclitaxel alone group. Bevacizumab was well tolerated in the maintenance setting with <1% grade 3–4 hematologic toxicities and no grade 3 or 4 nausea, ...
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II... This trial compared the efficacy and toxicity of standard first-line treatment with paclitaxel/carboplatin versus paclitaxel/carboplatin plus sora...